<DOC>
	<DOCNO>NCT01467700</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Ramelteon , daily ( QD ) , sublingual ( SL ) , adult participant acute depressive episode associate Bipolar I disorder .</brief_summary>
	<brief_title>Efficacy Safety Ramelteon Sublingual Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder</brief_title>
	<detailed_description>Ramelteon sublingual formulation develop Takeda Pharmaceutical Company Limited maintenance therapy Bipolar I disorder . Participants see twice first week treatment , weekly first 2 week treatment every 2 week end 8-week treatment period . Participants complete 8-week treatment period follow-up visit approximately seven day last visit . A safety follow-up phone call make 30 day completion 8-week treatment period . Based recommendation Independent Data Monitoring Committee determine study data meet pre-determined criterion futility , Takeda make decision terminate study . No safety concern identify Independent Data Monitoring Committee</detailed_description>
	<mesh_term>Depression</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant man woman age 18 75 year , inclusive . 4 . The participant suffers Bipolar I Disorder , Most Recent Episode Depressed primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.5x ) confirm Structured Clinical Interview DSM Disorders ( SCID ) . 5 . The report duration current Major Depressive Episode ( MDE ) least four week less 6 month . 6 . The participant Young Mania Rating Scale ( YMRS ) score ≤10 Screening Baseline visit . 7 . The participant MontgomeryÅsberg Depression Rating Scale ( MADRS ) total score ≥24 Screening Baseline Visits . 8 . The participant Clinical Global Impression Scale Severity ( CGIS ) score ≥4 Screening Baseline Visits . 9 . Hamilton Rating Scale Anxiety ( HAMA ) score ≤21 Screening Baseline visit . 10 . The participant lithium and/or valproate level within therapeutic range ( 0.6 1.2 mEq/L lithium 50125 mcg/ml valproate ) screening . If patient lithium and/or valproate level within therapeutic range screening , must lithium and/or valproate level within therapeutic range Day 15 Day 30 screening . 11 . A female participant childbearing potential sexually active agrees use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . 12 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing informed consent duration study 30 day last dose . 1 . The participant receive investigational compound &lt; 30 day Screening 5 halflives prior Screening . 2 . The participant receive ramelteon previous clinical study ever use ramelteon . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 4 . The participant one following : Any current psychiatric disorder Bipolar I Disorder , Most Recent Episode Depressed define DSMIVTR , assess SCID . Current history : schizophrenia , unipolar depression psychotic feature , bipolar depression psychotic feature , psychotic disorder ( exception psychosis associate manic episode ) , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Current diagnosis history alcohol substance abuse dependence ( exclude nicotine caffeine ) define DSMIVTR full sustain remission least one year day screening . ( Participant must also negative urine drug screen prior Baseline ) . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . Any Axis II disorder might compromise study . History Rapid Cycling Bipolar Disorder : Patients 8 episode mood disorder per year . 5 . The participant experience first episode mood disorder age 65 year . 6 . The current depressive symptom participant consider investigator resistant 2 adequate treatment trial mood stabilizer ( specifically start treat current depressive episode ) and/or antidepressant medication least 6 week duration . 7 . The participant psychotropic medication except lithium ( serum level 0.8 mEq/L ) valproate ( serum level 50 125 mcg/ml ) Screening visit . 8 . The participant lithium and/or valproate le 30 day prior screen . 9 . If participant antidepressant medication and/or antipsychotic medication ( use mood stabilizer ) patient consider appropriate PI , medication must wash least 2 week prior Screening visit . 10 . The participant receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . 11 . The participant start receive formal cognitive behavioral therapy , systematic psychotherapy within 30 day prior screen plan initiate therapy study . 12 . The participant significant risk suicide accord investigator 's clinical judgment score ≥ 5 item 10 ( suicidal thought ) MADRS make suicide attempt previous 6 month . 13 . The participant take anticipated participant take least 1 disallow concomitant medication . 14 . The participant clinically significant unstable illness , example hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , hematological , infectious , dermatological disorder metabolic disturbance determine Investigator . 15 . The participant history current diagnosis Fibromyalgia , Chronic Fatigue Syndrome , Chronic Pain Syndrome Sleep apnea . 16 . The participant previous history cancer remission le 5 year prior first dose study medication . This criterion include participant basal cell stage I squamous cell carcinoma skin . 17 . The participant 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant ; participant follow value Screening Visit : A serum creatinine value &gt; 1.5 time upper limit normal ( xULN ) . A serum total bilirubin value &gt; 1.5 xULN . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 xULN . 18 . The participant glycosylated hemoglobin ( HbA1C ) ≥7 % baseline prior diagnosis diabetes and/or treatment diabetes . NOTE : Participants know diabetes exclude . 19 . The participant thyroid stimulate hormone ( TSH ) value outside normal range Screening Visit deem clinically significant investigator . If TSH outside normal range , free T4 obtain . 20 . The participant clinically significant abnormal vital sign determine investigator . 21 . The participant abnormal electrocardiogram ( ECG ) determine central reader confirm clinically significant investigator . 22 . The participant disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 23 . The participant , opinion investigator , unlikely comply clinical study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>